These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34231442)

  • 41. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
    Cena H; Chiovato L; Nappi RE
    J Clin Endocrinol Metab; 2020 Aug; 105(8):e2695-709. PubMed ID: 32442310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GLP-1 receptor agonists and cardiovascular outcome trials: An update.
    Andrikou E; Tsioufis C; Andrikou I; Leontsinis I; Tousoulis D; Papanas N
    Hellenic J Cardiol; 2019; 60(6):347-351. PubMed ID: 30528435
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
    Brown JD; McAnally D; Ayala JE; Burmeister MA; Morfa C; Smith L; Ayala JE
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R595-R608. PubMed ID: 29949410
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
    Burcelin R; Gourdy P
    Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons.
    Adams JM; Pei H; Sandoval DA; Seeley RJ; Chang RB; Liberles SD; Olson DP
    Diabetes; 2018 Aug; 67(8):1538-1548. PubMed ID: 29776968
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
    Madsbad S
    Expert Rev Cardiovasc Ther; 2019 May; 17(5):377-387. PubMed ID: 31055989
    [No Abstract]   [Full Text] [Related]  

  • 47. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
    Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
    Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
    Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
    Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.
    Ryan D; Acosta A
    Obesity (Silver Spring); 2015 Jun; 23(6):1119-29. PubMed ID: 25959380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
    Ottney A
    Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
    Killion EA; Wang J; Yie J; Shi SD; Bates D; Min X; Komorowski R; Hager T; Deng L; Atangan L; Lu SC; Kurzeja RJM; Sivits G; Lin J; Chen Q; Wang Z; Thibault SA; Abbott CM; Meng T; Clavette B; Murawsky CM; Foltz IN; Rottman JB; Hale C; Véniant MM; Lloyd DJ
    Sci Transl Med; 2018 Dec; 10(472):. PubMed ID: 30567927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
    Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy.
    Bzowyckyj A
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):7-16. PubMed ID: 32910488
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
    Guyton J; Jeon M; Brooks A
    Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Practical guidance for use of oral semaglutide in primary care: a narrative review.
    Morales J; Shubrook JH; Skolnik N
    Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
    Sauer N; Reining F; Schulze Zur Wiesch C; Burkhardt T; Aberle J
    Horm Metab Res; 2015 Jul; 47(8):560-4. PubMed ID: 25230325
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Semaglutide for Weight Loss: Was It Worth the Weight?
    Novograd J; Mullally J; Frishman WH
    Cardiol Rev; 2022 Nov-Dec 01; 30(6):324-329. PubMed ID: 36201244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.